Related Experiment Videos
The coagulation system is activated in idiopathic cardiomyopathy
K Yamamoto1, U Ikeda, K Furuhashi
1Department of Cardiology, Jichi Medical School, Tochigi, Japan.
Journal of the American College of Cardiology
|June 1, 1995
Summary
This study reveals elevated markers of coagulation activation in hypertrophic and dilated cardiomyopathy patients. These changes may stem from left atrial dilation or left ventricular dysfunction, impacting thromboembolic risk.
Area of Science:
- Cardiology
- Hematology
- Biochemistry
Background:
- Thromboembolic events are significant complications in idiopathic cardiomyopathy.
- The precise triggers for coagulation system activation in these conditions remain under-investigated.
Purpose of the Study:
- To investigate plasma markers of platelet activity, thrombotic, and fibrinolytic status in hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
- To identify the site of coagulation activation in these cardiomyopathies.
Main Methods:
- Measured plasma levels of platelet factor 4, beta-thromboglobulin, fibrinopeptide A, thrombin-antithrombin III complex, D-dimer, and plasmin-alpha 2-plasmin inhibitor complex.
- Compared levels in 13 HCM patients, 17 DCM patients, and 20 healthy controls.
Main Results:
- Fibrinopeptide A and thrombin-antithrombin III complex were significantly elevated in both HCM and DCM groups compared to controls.
- D-dimer levels were higher in DCM patients than in HCM patients and controls.
- Specific correlations were found between coagulation markers and cardiac dimensions/function in both patient groups.
Conclusions:
- The coagulation system is activated in HCM and DCM.
- Left atrial dilation may trigger coagulation in HCM.
- Left ventricular enlargement and dysfunction may trigger coagulation in DCM.